Welcome to our dedicated page for Bausch Health Companies news (Ticker: BHC), a resource for investors and traders seeking the latest updates and insights on Bausch Health Companies stock.
Bausch Health Companies Inc. (NYSE: BHC, TSX: BHC) generates a wide range of news relevant to investors, health care professionals and industry observers. As a global, diversified pharmaceutical company with operations in gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, its disclosures cover both business performance and strategic activity.
News updates commonly include financial results and segment performance, such as quarterly revenue trends across Salix, International, Solta Medical, Diversified Products and Bausch + Lomb. The company also releases information on capital structure actions, including exchange offers for senior secured notes and amendments to credit agreements at Bausch Health and Bausch + Lomb, which are detailed in press releases and Form 8-K filings.
Bausch Health’s news flow highlights business development and acquisitions, for example the acquisition of DURECT Corporation to expand its hepatology portfolio and the acquisition of Wuhan Shibo Zhenmei Technology Co., Ltd. to strengthen Solta Medical’s distribution in China. Product and geographic expansion updates, such as OraPharma’s commercial expansion into Canada and Puerto Rico and regulatory milestones for aesthetic devices, also feature prominently.
In addition, the company announces conference participation and investor events, including presentations at healthcare conferences where management provides strategic and business updates and may discuss guidance ranges. For those tracking BHC, this news page offers a centralized view of official announcements on operations, financing, governance and growth initiatives. Investors and followers of the pharmaceutical and medical aesthetics sectors can review these items to understand how Bausch Health is executing on its stated priorities and managing its diversified portfolio.
Bausch Health Companies Inc. (NYSE/TSX: BHC) announced plans to appeal a recent U.S. District Court ruling regarding its XIFAXAN® patents. The court ruled the patents for the treatment of overt hepatic encephalopathy as valid but declared those for irritable bowel syndrome with diarrhea invalid. Bausch intends to challenge this ruling vigorously and prevent Norwich Pharmaceuticals from launching a generic version of XIFAXAN® until at least 2029. The FDA is also revising guidance for rifaximin, which may impact future generic approvals.
Bausch Health Companies Inc. (NYSE/TSX: BHC) will announce its second-quarter financial results on August 9, 2022, at 8:00 a.m. ET. A conference call and live webcast will follow, providing insights into the company's performance and business updates. Interested parties can access the materials through the Investor Relations section of Bausch Health's website. The company is focused on improving lives through its diverse portfolio in various health sectors, including gastroenterology and dermatology.
Bausch + Lomb Corporation (NYSE/TSX: BLCO) has appointed Thomas W. Ross, Sr. as the new chair of the Board of Directors following the resignation of Joseph C. Papa. Mr. Papa remains CEO until a successor is found. The Board is actively searching for a new CEO while affirming the company's full-year guidance for 2022, initially announced on June 8. The company aims to complete its spinoff from Bausch Health (NYSE/TSX: BHC) in 2023, contingent on various approvals and market conditions, with no reported disagreements leading to Mr. Papa's departure.
Bausch Health Companies Inc. (NYSE/TSX: BHC) and Salix Pharmaceuticals announced the winners of the 2022 Salix Gastrointestinal Health Scholars Program, awarding $10,000 each to 10 students living with gastrointestinal diseases. This marks the third consecutive year of the program which received over 150 applications. The scholarship aims to assist students in their academic pursuits amid health challenges. The recipients span undergraduate and graduate categories, showcasing the company's commitment to supporting education for those impacted by GI conditions.
Bausch Health Companies Inc. (NYSE/TSX: BHC) announced the results of its 2022 annual meeting of shareholders held on June 21, 2022. All 12 nominated directors were elected, with Thomas J. Appio as CEO expressing gratitude towards former Board member Joseph C. Papa who resigned. John A. Paulson fills the vacancy and will serve as Board Chair. Shareholders approved executive compensation, amendments to the 2014 Omnibus Incentive Plan, and appointed PricewaterhouseCoopers LLP as the independent auditor until the 2023 meeting. Full voting results will be reported on Form 8-K.
Bausch Health Companies Inc. (NYSE/TSX: BHC) has announced its presentation during the Annual Meeting of Shareholders held on June 21, 2022. The presentation highlights the company's diversified pharmaceutical operations, focusing on improving health outcomes through various products in gastroenterology, neurology, and eye health, primarily via its ownership of Bausch + Lomb. The company has also filed a Form 8-K detailing this presentation, available on its Investor Relations page, reinforcing its commitment to advancing global health.
Bausch Health Companies Inc. (NYSE/TSX: BHC) and its gastroenterology business, Salix Pharmaceuticals, will present new data on XIFAXAN® (rifaximin) at the European Association for the Study of the Liver's International Liver Congress™ 2022 in London from June 22-26, 2022. The research focuses on identifying factors precipitating overt hepatic encephalopathy (OHE) and aims to improve management strategies, reducing hospitalization risks. Salix, dedicated to addressing liver disease, emphasizes its role in enhancing patient care through research and development.
Bausch Health Companies (NYSE/TSX: BHC) announced it is suspending the IPO plans for its Solta Medical business due to challenging market conditions. Solta, a leader in medical aesthetics, offers advanced skin rejuvenation and body contouring solutions. The company aims to focus on driving Solta's revenue and operational milestones while retaining it within the Bausch Health portfolio to aid in deleveraging its balance sheet. CEO Thomas J. Appio expressed confidence in Solta's growth and market potential.
Bausch Health Companies Inc. (NYSE/TSX: BHC) announced that it will present seven research posters for its products XIFAXAN®, TRULANCE®, and PLENVU® at Digestive Disease Week 2022 from May 21-24, 2022, in San Diego, California. The posters highlight significant findings, such as the efficacy of XIFAXAN in managing hepatic encephalopathy and IBS-D, TRULANCE's rapid response in treating IBS-C, and PLENVU’s high-quality bowel cleansing for colonoscopy preparations. The research results will be publicly accessible on DDW's ePoster website starting May 21, 2022.
KBRA has published its First-Quarter 2022 U.S. Bank Compendium, offering insights into the banking sector's performance. The report highlights the impact of inflation on vehicle prices and auto loan exposures within the KBRA-rated banks. It includes summaries of 1Q22 results for publicly traded U.S. banks, focusing on key performance metrics and credit ratios. Additionally, the Compendium features the top 10 low-cost deposit franchises and a detailed supplement of 171 debt issues rated by KBRA.